Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

CAR2.0 Therapy for the Management of Post-Transplantation Relapse of B-Cell Acute Lymphoblastic Leukemia

Blood (2020) 136 (Supplement 1): 7.

https://doi.org/10.1182/blood-2020-141531

Published: 2020

Journal Articles

Improved Safety and Efficacy of a Multi-Target Chimeric Antigen Receptor Modified T Cell Therapy (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Rui Zhang, MSc, Yuhua Li, MD& PhD, Sanfang Tu, MD& PhD, Rui Huang, MD& PhD, Xun Lai, MD, Leping Zhang, MD PhD, Eugene E. Zvonkov, MD PhD, Valeriy G. Savchenko, MD PhD, Nelly G Gabeeva, PhD, Yuchen Liu, MSc, Yuchen Li, MSc, Cheng Jiao, MD PhD, Lan Deng, MD PhD, Xuan Zhou, MD, Hongyu Zhang, MD PhD, Wenli Zhang, MD, Lung-Ji Chang, PhD

Blood (2020) 136 (Supplement 1): 47.

https://doi.org/10.1182/blood-2020-141515

Published: 2020

Journal Articles

A Novel Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD123 to Treat Relapsed Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Sanfang Tu, MD PhD, Lan Deng, MD PhD, Rui Huang, MD PhD, Xuan Zhou, MD, Jilong Yang, MD, Weijun Zhou, MD PhD, Meifang Li, MD PhD, Chunyan Yue, MD, Shaojie Wu, MD PhD, Zhenling Guo, Lung-Ji Chang, PhD, Yuhua Li, MD PhD

Blood (2018) 132 (Supplement 1): 4015.

https://doi.org/10.1182/blood-2018-99-118526

Published: 2018

Journal Articles

Combination of CD19 and CD70 Specific Chimeric Antigen Receptor T Cells Achieves Long-Term Disease-Free Survival in Relapsed and Refractory Primary Central Nervous System Diffuse Large B Cell Lymphoma

Sanfang Tu, MD PhD, Rui Huang, MD PhD, Xuan Zhou, MD, Yanjie He, MD PhD, Zhao Liang, MD PhD, Lei Wang, MD PhD, Lung-Ji Chang, PhD, Yuhua Li, MD PhD

Blood (2018) 132 (Supplement 1): 5389.

https://doi.org/10.1182/blood-2018-99-117694

Published: 2018

Journal Articles

Therapy of 4s Chimeric Antigen Receptor T Cells Achieves Long-Term Disease-Free Survival with No Severe CRS or Cres in Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia

Sanfang Tu, MD PhD, Rui Huang, MD PhD, Lan Deng, MD PhD, Xuan Zhou, MD, Yanjie He, MD PhD, Weijun Zhou, MD PhD, Jilong Yang, MD, Chunyan Yue, MD, Anqin Wu, Meifang Li, MD PhD, Zhenling Guo, Lung-Ji Chang, PhD, Yuhua Li, MD PhD

Blood (2018) 132 (Supplement 1): 2696.

https://doi.org/10.1182/blood-2018-99-118928

Published: 2018

Journal Articles

Phase I/II Trial of Multi-Target Chimeric Antigen Receptor Modified T Cells (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Lung-Ji Chang, PhD, Yuhua Li, MD& PhD, Sanfang Tu, MD& PhD, Xun Lai, MD, Rui Huang, MD& PhD, Shih-Ting Tsao, MSc, Yu-Chen Liu, MSc, Rui Zhang, MSc, Lan Deng, MDPhD, Xuan Zhou, MD, Hongyu Zhang, PhD MD, Wenli Zhang, MD, Yuchen Li, MSc

Blood (2018) 132 (Supplement 1): 225.

https://doi.org/10.1182/blood-2018-99-114396

Published: 2018

Journal Articles

Durable Remission after Salvage Chemotherapy with Combining Bortezomib and Vorinostat Followed By CD19 CAR-T Therapy in a Patient with MLL-Rearranged ALL after Early Relapse Post Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2017) 130 (Supplement 1): 3334.

https://doi.org/10.1182/blood.V130.Suppl_1.3334.3334

Published: 2017

Journal Articles

Chimeric Antigen Receptor 4SCAR-GD2-Modified T Cells Targeting High-Risk and Recurrent Neuroblastoma: A Phase II Multi-Center Trial in China

Lihua Yang, MDPhD, Xiaoli Ma, MDPhD, Yu-Chen Liu, MSc, Wen Zhao, MDPhD, Lihua Yu, PhD, Maoquan Qin, MDPhD, Guanghua Zhu, MDPhD, Kai Wang, MDPhD, Xiaodong Shi, MD, Zhaoxia Zhang, MD, Jingfu Wang, MD, Yuan Sun, MD, Lujia Dong, MD, Shih-Ting Tsao, MSc, Rui Zhang, MSc, Lung-Ji Chang, PhD

Blood (2017) 130 (Supplement 1): 3335.

https://doi.org/10.1182/blood.V130.Suppl_1.3335.3335

Published: 2017

Journal Articles

Double CD19/CD22 Chimeric Antigen Receptor-Modified T Cells for the Treatment of Stage IV Relapsed and Refractory Follicular Lymphoma

Xun Lai, MD, Xuezhong Gu, MD, Shih-Ting Tsao, MSc, Qin Zhang, PhD, Yu-Chen Liu, MSc, Jiang Yaxian, PhD, Li Yan, MD, Jun Chun, MD, Rui Zhang, MSc, Yunyun Du, MD, Xiaoli Gao, MD, Yingyu Yang, Xiaolian Qiu, Mingjing Fang, MA, Song Wei, PhD, Lung-Ji Chang, PhD

Blood (2017) 130 (Supplement 1): 5154.

https://doi.org/10.1182/blood.V130.Suppl_1.5154.5154

Published: 2017

Journal Articles

CD19 Epitope Escape after 4SCAR19 T Cell Therapy Resulted in Re-Establishment of Chemo-Sensitivity in Adult B-Cell Acute Lymphocytic Leukemia Patients

Xun Lai, MD, Jian-Qiong Liu, MD, Lujia Dong, MD, Hong-Mei Ou-Yang, PhD, Zi-Jin Dian, PhD, Jian-Xin Song, PhD, Ya-Xian Jiang, PhD, Xiang-Mei Yao, MD, Xue-Zhong Gu, MD, Xiao-Li Gao, MD, Ya-Yun Wu, MD, Lung-Ji Chang, PhD

Blood (2016) 128 (22): 1633.

https://doi.org/10.1182/blood.V128.22.1633.1633

Published: 2016

Journal Articles

Safety and Efficacy Evaluation of 4SCAR19 Chimeric Antigen Receptor-Modified T Cells Targeting B Cell Acute Lymphoblastic Leukemia - Three-Year Follow-up of a Multicenter Phase I/II Study

Lung-Ji Chang, PhD, Lujia Dong, MD, Yu-Chen Liu, MSc, Shih-Ting Tsao, MSc, Ya-Chen Li, PhD, Li Liu, MD, Zhiyong Gao, MD, Xiyou Tan, MD, Dao-Pei Lu, MD, Jian-Ping Zhang, Jing-Bo Wang, Yu-Ming Ying, MD, Le-Ping Zhang, MD, Huyong Zheng, MD PhD, Kai Wang, MD PhD, Xiao-Li Zheng, MD, Heng-Xiang Wang, MD, Xun Lai, MD, Dong Li, MD

Blood (2016) 128 (22): 587.

https://doi.org/10.1182/blood.V128.22.587.587

Published: 2016

Journal Articles

4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass

Lung-Ji Chang, PhD, Lujia Dong, MD, Jun Zhu, MD, Zhitao Ying, MD, Hao-Hsian Kuo, MSc, Yuchen Liu, MSc, Yu-Qin Song, MD, Xiao-Pei Wang, MD, Yong-Qian Jia, MD, Ting Niu, MD PhD, Ting Liu, MDPhD, Ling Pan, MD, Zhuo-Gang Liu, MD, Tong Li, MD, Ying-Chun Li, MD, Kun Yao, MD, Xiaoyan Ke, MD PhD, Hongmei Jing, MD, Fang Bao, MD

Blood (2015) 126 (23): 264.

https://doi.org/10.1182/blood.V126.23.264.264

Published: 2015

Journal Articles

Rescue of a Terminally Ill Patient with Chemo-Refractory Acute Lymphoblastic Leukemia Carrying Bcr/Abl and TP53 Mutations Based on a 4th Generation CD19 Chimeric Antigen Receptor-Engineered T (CAR-T) Therapy

Ting Niu, MD PhD, Lung-Ji Chang, PhD, Jinrong Yang, MD, Yuchen Liu, MSc, Lujia Dong, MD, Wei Wang, PhD, Ting Liu, MD

Blood (2015) 126 (23): 5431.

https://doi.org/10.1182/blood.V126.23.5431.5431

Published: 2015

Journal Articles

Up-Regulation of CAR-T Cells after G-CSF and Dexamethasone Treatment in a Defuse Large B Cell Lymphoma Patient Receiving 4SCAR19 T Cell Therapy

Hongmei Jing, MD, Lung-Ji Chang, PhD, Mingyi Chen, MD PhD, Fang Bao, MD, Jing Wang, Wenming Wang, Yuanyuan Liu, Hao-Hsian Kuo, MSc, Yuchen Liu, MSc, Lujia Dong, MD

Blood (2015) 126 (23): 5130.

https://doi.org/10.1182/blood.V126.23.5130.5130

Published: 2015

Journal Articles

Chimeric Antigen Receptor 4SCAR19-Modified T Cells in Acute Lymphoid Leukemia: a Phase II Multi-Center Clinical Trial in China

Lujia Dong, MD, Lung-Ji Chang, PhD, Zhiyong Gao, MD, Dao-Pei Lu, MD, Jian-Ping Zhang, MD, Jing-Bo Wang, MD, Le-Ping Zhang, MD, Yu-Hong Chen, MD, Hu-Yong Zheng, MD, Ting Liu, Ting Niu, MD PhD, He Huang, MD PhD, Rong Liu, MD, Heng-Xiang Wang, MD, Li Gao, MD, Tong-Hua Yang, MD, Xun Lai, MD

Blood (2015) 126 (23): 3774.

https://doi.org/10.1182/blood.V126.23.3774.3774

Published: 2015

Journal Articles

First-in-Man CD123-Specific Chimeric Antigen Receptor-Modified T Cells for the Treatment of Refractory Acute Myeloid Leukemia

Yi Luo, Lung-Ji Chang, PhD, Yongxian Hu, MD, Lujia Dong, Guoqing Wei, He Huang, MD PhD

Blood (2015) 126 (23): 3778.

https://doi.org/10.1182/blood.V126.23.3778.3778

Published: 2015

Journal Articles

HLA Disparity Is Associated with Improved Outcomes in Hematological Malignancies After Family HLA-Mismatched /Haploidentical HCT but Not URD

Lujia Dong, M.D., Zhi-Yong Gao, M.D., Xin-Jian Yu, M.D., Xi-You Tan, M.D., Jin-Hong Liu, M.D., Fengjuan Lu, M.D., Yi Xie, M.D., Lung-Ji Chang, PhD, Ling Zhou, M.D., Wen-Rong Lu, M.D., Can Tong, M.D., Yuan-Ying Zeng, M.D., Shuang Hou, M.D., Na Xu, M.D., Xue Yan, M.S., Dao-Pei Lu, M.D.

Blood (2012) 120 (21): 2014.

https://doi.org/10.1182/blood.V120.21.2014.2014

Published: 2012

Journal Articles

Characterization and Immunotherapeutic Implication of a Novel Cerebro-Spinal Fluid-Derived ALK-Positive Anaplastic Large Cell Lymphoma Cell Line

Li-Jun Yang, MD, Shuhong Han, PhD, Hai Wang, MD/PhD, Merry-Jennifer Markham, MD, Brian A Gray, MS, Westley Reeves, MD, Lung-Ji Chang, PhD

Blood (2012) 120 (21): 5096.

https://doi.org/10.1182/blood.V120.21.5096.5096

Published: 2012

Journal Articles

Adoptive Immune Cell Therapy for the Control of Fungal Infections in Hematopoietic Stem Cell Transplant Patients

Lung-Ji Chang, PhD, Yin Liang, Lily Lien, Chun- Rong Tong, MD, Lu-Jia Dong, MD, Tong Wu, MD, Yinchieh Fu, Fu-Hung Yang, Jih-Luh Tang, MD, PhD, Dao-Pei Lu, MD

Blood (2008) 112 (11): 4358.

https://doi.org/10.1182/blood.V112.11.4358.4358

Published: 2008

Journal Articles

Escape of Minor Histocompatibility Antigen-Restricted Anti-Leukemia Immunity Associated with Loss of Specific HLA-I Locus Expression in a Leukemia Patient after an Intensive Immunotherapy.

Lung-Ji Chang, PhD, Chun-Rong Tong, MD, Jih-Luh Tang, MD PhD, Yoshiki Akatsuka, MD PhD, Shuhong Han, PhD, Yin Liang, MSc, Chi-Cheng Li, MD, Lujia Dong, MD, Tong Wu, MD, Dao-Pei Lu, MD

Blood (2007) 110 (11): 4895.

https://doi.org/10.1182/blood.V110.11.4895.4895

Published: 2007

NARROW

CAR2.0 Therapy for the Management of Post-Transplantation Relapse of B-Cell Acute Lymphoblastic Leukemia

Improved Safety and Efficacy of a Multi-Target Chimeric Antigen Receptor Modified T Cell Therapy (4SCAR2.0) Against Relapsed or Refractory Lymphomas

A Novel Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD123 to Treat Relapsed Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Combination of CD19 and CD70 Specific Chimeric Antigen Receptor T Cells Achieves Long-Term Disease-Free Survival in Relapsed and Refractory Primary Central Nervous System Diffuse Large B Cell Lymphoma

Therapy of 4s Chimeric Antigen Receptor T Cells Achieves Long-Term Disease-Free Survival with No Severe CRS or Cres in Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia

Phase I/II Trial of Multi-Target Chimeric Antigen Receptor Modified T Cells (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Durable Remission after Salvage Chemotherapy with Combining Bortezomib and Vorinostat Followed By CD19 CAR-T Therapy in a Patient with MLL-Rearranged ALL after Early Relapse Post Allogeneic Hematopoietic Stem Cell Transplantation

Chimeric Antigen Receptor 4SCAR-GD2-Modified T Cells Targeting High-Risk and Recurrent Neuroblastoma: A Phase II Multi-Center Trial in China

Double CD19/CD22 Chimeric Antigen Receptor-Modified T Cells for the Treatment of Stage IV Relapsed and Refractory Follicular Lymphoma

CD19 Epitope Escape after 4SCAR19 T Cell Therapy Resulted in Re-Establishment of Chemo-Sensitivity in Adult B-Cell Acute Lymphocytic Leukemia Patients

Safety and Efficacy Evaluation of 4SCAR19 Chimeric Antigen Receptor-Modified T Cells Targeting B Cell Acute Lymphoblastic Leukemia - Three-Year Follow-up of a Multicenter Phase I/II Study

4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass

Rescue of a Terminally Ill Patient with Chemo-Refractory Acute Lymphoblastic Leukemia Carrying Bcr/Abl and TP53 Mutations Based on a 4th Generation CD19 Chimeric Antigen Receptor-Engineered T (CAR-T) Therapy

Up-Regulation of CAR-T Cells after G-CSF and Dexamethasone Treatment in a Defuse Large B Cell Lymphoma Patient Receiving 4SCAR19 T Cell Therapy

Chimeric Antigen Receptor 4SCAR19-Modified T Cells in Acute Lymphoid Leukemia: a Phase II Multi-Center Clinical Trial in China

First-in-Man CD123-Specific Chimeric Antigen Receptor-Modified T Cells for the Treatment of Refractory Acute Myeloid Leukemia

HLA Disparity Is Associated with Improved Outcomes in Hematological Malignancies After Family HLA-Mismatched /Haploidentical HCT but Not URD

Characterization and Immunotherapeutic Implication of a Novel Cerebro-Spinal Fluid-Derived ALK-Positive Anaplastic Large Cell Lymphoma Cell Line

Adoptive Immune Cell Therapy for the Control of Fungal Infections in Hematopoietic Stem Cell Transplant Patients

Escape of Minor Histocompatibility Antigen-Restricted Anti-Leukemia Immunity Associated with Loss of Specific HLA-I Locus Expression in a Leukemia Patient after an Intensive Immunotherapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only